Neupulse Closes $3.2M Seed Financing to Advance World’s First Wearable Device for Tourettes Syndrome
Neupulse has secured a $3.2 million seed-stage investment led by Scottish impact investor Eos Advisory, alongside a consortium of US-based investors, to advance the world’s first wearable device for Tourette’s Syndrome (TS) and other tic disorders towards commercialization as the Nottingham, UK-based company moves towards the regulatory approval phase in the UK, Europe and the US.
Neupulse’s recently completed working prototype stimulates the median nerve in the wrist to reduce the frequency of tics in people with TS, a condition thought to affect up to 2% of the world’s child population and 1% of the general population. Clinical trials in 2023 showed that the Neupulse device can reduce tics by more than 25 percent.
Tourettes Syndrome is a debilitating condition, severely so in many cases and to the detriment of quality of life, and our mission is to drastically reduce tics with an easy-to-use wearable device that will be transformative to the lives of affected individuals. Our device is an alternative to the current provision of treatment for TS, which is centred around medication and cognitive behaviour therapy. The goal is for Neupulse to be available to the TS community globally in the years ahead,” said Paul Cable, CEO of Neupulse, the trading name for Neurotherapeutics Ltd. which was founded as a spinout from the University of Nottingham in 2021.
Eos was set up to back science-based companies and founders developing technologies that can positively impact the lives of people across the globe. Whilst we are focussed on Scottish startups, when one of our investors brought the amazing work of Neupulse to our attention we realised that there was a huge opportunity to add value, well beyond the investment, to help bring this device to market and improve the lives of people affected by TS and related conditions. What’s even more exciting, is how the nascent technology could be beneficial for many other neural conditions in the future,” said Ana Stewart, Partner of Eos Advisory.
